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CONCLUSION
Brugada Syndrome is a rare genetic mutation 
caused by a disruption of proteins regulating cardiac 
sodium channels effecting 0.012 to 0.4% of the U.S. 
population with type 1 pattern being the rarest of 
the 3 classic patterns.1  The type 1 ECG pattern has 
coved ST-segment elevation in V1-V32, and patients 
can present asymptomatic, with syncope or sudden 
cardiac death (SCD).1
Brugada syndrome is a rare, but critical diagnosis which cannot be 
missed as the risk of sudden cardiac death is greatly increased from 
the normal population.  This case emphasizes the need for recurrent 
evaluation in patient with Brugada pattern on ECG.
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METHODS
A 52 y/o male presented as a transfer to our facility 
after a syncopal event in his vehicle.  The patient 
was a previously healthy male with no family history 
of SCD.  At the outside facility, he was found to have 
rhabdomyolysis, severe electrolyte abnormalities and 
Brugada type I pattern, so he was transferred to our 
facility for Electrophysiology (EP) evaluation. 
Images 1: Electrocardiogram demonstrating Type I Brugada 
pattern.
Figure 1: Electrocardiogram patterns of Brugada syndrome.  Only 
a type 1 ECG allows diagnosis of Brugada syndrome.  Positive 
sodium channel blocker testing is required for types 2 and 3 to 
diagnose Brugada syndrome. (1)
Figure 2: Indication for implantation of an implantable 
cardioverter defibrillator (ICD), according to the risk of sudden 
cardiac death (SCD). The risk of SCD is represented with a red 
arrow. The red boxes represents an indication for ICD implantation; 
the green box represents a patient who should not be implanted, 
according to the latest guidelines; the orange boxes are not 
addressed in the guidelines. (1)
The patient underwent a flecainide challenge and EP study, which was 
inconclusive and he was discharged on metoprolol.  He followed up 
with EP as an outpatient and was noted on routine ECG to have return 
of his Brugada Type 1 pattern.  He underwent successful implantation 
of a defibrillator for primary prevention of SCD due to high risk features 
of prior syncope, recurrent Brugada pattern, and male age.
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